AMG 319

AMG 319 is a drug developed by Amgen which acts as an inhibitor of the phosphoinositide 3-kinase enzyme subtype PI3Kδ. It was originally developed as an anti-inflammatory drug with potential applications in the treatment of autoimmune conditions such as rheumatoid arthritis, but subsequent research showed that it inhibits cell proliferation and might potentially have useful anti-cancer effects, and it has been put into clinical trials to assess its safety and tolerability in this application.^[1][2]

AMG 319

Clinical data
ATC code	None
Legal status
Legal status	Investigational
Identifiers
IUPAC name (S)-N-(1-[7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl]ethyl)-9H-purin-6-amine
CAS Number	1608125-21-8 Y
PubChem CID	68947304
ChemSpider	35000181
UNII	19DG7G1U5Q
CompTox Dashboard (EPA)	DTXSID501046373
Chemical and physical data
Formula	C21H16FN7
Molar mass	385.406 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@H](c1cc2ccc(cc2nc1c3ccccn3)F)Nc4c5c([nH]cn5)ncn4
InChI InChI=1S/C21H16FN7/c1-12(28-21-19-20(25-10-24-19)26-11-27-21)15-8-13-5-6-14(22)9-17(13)29-18(15)16-4-2-3-7-23-16/h2-12H,1H3,(H2,24,25,26,27,28)/t12-/m0/s1 Key:KWRYMZHCQIOOEB-LBPRGKRZSA-N

Mechanism(s) of action

It is a potential immunotherapy because blocking PI3Kδ (PI3K p110δ) eliminates a group of inhibitory immune cells and may allow the immune system to better attack the cancer cells.^[3]

Clinical trials

Its first clinical trial was a phase I/II study in adults with relapsed or refractory lymphoid malignancies.^[4] This was due to run from 2011 to 2013.^{[citation needed]}

In 2015/16 it started a phase II clinical trial as a neoadjuvant therapy for human papillomavirus (HPV) negative head and neck squamous-cell carcinoma (HNSCC) (prior to resection surgery).^[3]

See also

• Duvelisib
• Idelalisib